Nasdaq atai.

Get ATAI Life Sciences BV (ATAI) share price today and stock analysis, price valuation, performance, fundamentals, market cap, shareholding, ...Find the latest Insider Activity data for ATAI Life Sciences N.V. Common Shares (ATAI) at Nasdaq.com. ... Nasdaq Insider Activity page provides trading information of corporate insiders (officers ...The atai Impact program will be initially funded by 1% of the gross proceeds from our June 2021 IPO and founders’ and shareholders’ contributions. Third Quarter 2021 Financial Results. Cash ...Mar 6, 2023 · NEW YORK and BERLIN, March 06, 2023 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ: ATAI) (“atai”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental ...

ATAI Life Sciences N.V. Common Shares ... Nasdaq.com will report pre-market and after hours trades. Pre-Market trade data will be posted from 4:15 a.m. ET to 7:30 a.m. ET of the following day.

Short Interest. Many investors believe that rising short interest positions in a stock is a bearish indicator. They use the Days to Cover statistic as a way to judge rising or falling sentiment in ... ATAI Life Sciences (Nasdaq: ATAI) atai Life Sciences Announces First Subject Dosed in Phase 1 Trial of Buccal and IV VLS-01, a Synthetic Form of DMT: The trial is a randomized, double-blind, placebo-controlled study designed to evaluate the relative bioavailability of buccal versus IV formulations, ...

NEW YORK and BERLIN, Oct. 12, 2022 (GLOBE NEWSWIRE) -- atai Life Sciences N.V. (Nasdaq: ATAI) (“atai”) announced today positive initial results for their Phase 1 clinical trial of KUR-101. KUR ...EVgo, Inc. (NASDAQ:EVGO) fell 14.3% to close at $16.19 following negative analyst coverage from Credit Suisse. Atai Life Sciences N.V. (NASDAQ:ATAI) dropped 13.8% to close at $12.85 following Q3 ...Atai Life Sciences ( NASDAQ: ATAI) has a somewhat unique business model, a decentralized platform that acquires and operates clinical programs that are separate companies or behave like them. It ...atai Life Sciences atai is a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders. atai was founded in 2018 as a response to the significant unmet ...ATA (Nasdaq: ATAI) is the largest professional services provider for testing, assessment and related services in China, as well as the most effective AI-enhanced Remote Invigilation products and ...

Nov 29, 2023 · The average trading volume of ATAI on November 29, 2023 was 536.92K shares. ATAI) stock’s latest price update. The stock price of ATAI Life Sciences N.V. (NASDAQ: ATAI) has plunged by -3.51 when compared to previous closing price of 1.14, but the company has seen a 2.80% gain in its stock price over the last five trading sessions.

Based on analysts offering 12 month price targets for ATAI in the last 3 months. The average price target is $ 0.00 with a high estimate of $ 0.00 and a low estimate of $ 0.00 .

Atai. On April 7, 2021, Atai Life Sciences , (NASDAQ: ATAI) a clinical-stage biopharmaceutical company developing psychedelics and non-psychedelic compounds for mental health wellness, acquired a majority stake in Delaware-based Psyber, a company working on a brain-to-computer (BCI) interface device. It is hoped that the Psyber brain-to ...Mar 6, 2023 · NEW YORK and BERLIN, March 06, 2023 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ: ATAI) (“atai”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental ... ATAI Life Sciences N.V. Common Shares (ATAI) Stock Price, Quote, News & History | Nasdaq MY QUOTES: ATAI Edit my quotes ATAI Life Sciences N.V. Common Shares (ATAI) 0 Add to Watchlist...ATAI Life Sciences N.V. (NASDAQ:ATAI)’s traded shares stood at 0.58 million during the last session, with the company’s beta value hitting 0.86. At the close of trading, the stock’s price was $1.32, to imply an increase of 6.45% or $0.08 in intraday trading. The ATAI share’s 52-week high ...ATAI Life Sciences N.V. Common Shares (ATAI) Real-time Stock Quotes - Nasdaq offers real-time quotes & market activity data for US and global markets. One of the key developments in the psychedelic industry over the past year and a half has been the stock market debut of companies like Atai Life Sciences N.V. (NASDAQ: ATAI), the German biopharma ...The latest price target for . ATAI Life Sciences (NASDAQ: ATAI) was reported by HC Wainwright & Co. on August 14, 2023.The analyst firm set a price target for $20.00 …

Based on 2 Wall Street analysts offering 12 month price targets for ATAI Life Sciences in the last 3 months. The average price target is $20.00 with a high ...atai Life Sciences (NASDAQ: ATAI) (“atai”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, announced that the first subject has been ...For ATAI Life Sciences NV (NASDAQ:ATAI), Canaccord Genuity initiated coverage, by setting the current rating at Buy. The stock has a 52-week-high of $22.91 and a 52-week-low of $16.50.ATAI Life Sciences (NASDAQ: ATAI) is a renowned global biopharmaceutical company specializing in developing innovative treatments for mental health disorders.The company has recently garnered ...The new research reports from Fundamental Markets, available for free download at the links above, examine Whiting Petroleum Corporation (NYSE:WLL), ATA Inc. (NASDAQ:ATAI), Ubiquiti Networks, Inc ...

Nov 14, 2023 · Clinical-stage psychedelics company atai Life Sciences (NASDAQ:ATAI) reported its financial results and corporate updates for the third quarter ended September 30, 2023. In numbers: Cash, cash ...

Apr 28, 2023 · NEW YORK and BERLIN, April 28, 2023 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ: ATAI) (“atai”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental ... ATAI ATAI Life Sciences. Close 12/01 16:00 ET. 1.120. +0.080 +7.69%. High 1.150 ... (NASDAQ:ATAI) shares closed up 4.67% at $1.12Mind Medi. Benzinga11-23 04:30 ET.The fund has raised an initial $35 million in capital and currently holds an active portfolio of 20 companies, including investments in Atai Life Sciences (NASDAQ: ATAI), Reset Pharma, Field Trip ...In this week’s Trade To Black Podcast, TDR Founder Shadd Dales and lead financial writer Benjamin A. Smith interview the founder of Apeiron Investment Group, Christian Angermayer.Aperion is best known in North America for its prominent investments in psychedelic biopharma leaders atai Life Sciences N.V. (NASDAQ: ATAI) and …COMPASS Pathways plc (NASDAQ: CMPS) and Atai Life Sciences N.V. (NASDAQ: ATAI) recently debuted on the stock market, fetching billion dollar valuations, while Seelos Therapeutics, Inc. (NASDAQ ...Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX. Copyright © 2007-2023 FINVIZ.com. All Rights Reserved. Quantcast. × ...atai Life Sciences N.V. (NASDAQ: ATAI), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, recently announced the launch of TryptageniX.Atai Life Sciences unit GABA Therapeutics upbeat about deuterated form of 1960s drug. The biopharma Atai Life Sciences (Nasdaq:ATAI) subsidiary GABA Therapeutics is sharing positive results from a Phase 1 study of GRX-917, a deuterated form of etifoxine, which the German firm Hoechst developed in the 1960s. Sanofi-Aventis …4 days ago ... Atai Life Sciences N.V.'s stock symbol is ATAI and currently trades under NASDAQ. It's current price per share is approximately $1.12. How much ...

To compile our list of the best German stocks to buy, we first made a list of all German firms that are trading on the NASDAQ and NYSE exchanges. Then, those firms with the greatest number of hedge fund investors during Q2 2023, and the top German stocks are as follows. 12 Best German Stocks To Buy Now 12. Atai Life Sciences N.V. (NASDAQ:ATAI)

Atai Life Sciences Nv 's revenue in 2023 is $334,000.On average, 2 Wall Street analysts forecast ATAI's revenue for 2023 to be $124,507,857, with the lowest ATAI revenue forecast at $49,803,143, and the highest ATAI revenue forecast at $199,212,571.

Nov 29, 2023 · 4 brokers have issued 1-year price targets for Atai Life Sciences' stock. Their ATAI share price targets range from $9.00 to $20.00. On average, they expect the company's stock price to reach $12.80 in the next twelve months. This suggests a possible upside of 1,063.6% from the stock's current price. Palm Beach, FL –December 14, 2021 – FinancialNewsMedia.com News Commentary – The prevalence of mental health disorders has risen exponentially, and the development of novel medications has not kept pace, precipitating a crisis in psychiatric medicine. A novel innovation is psychedelic drug-assisted psychotherapy – the medically …On February 16, Atai Impact, the philanthropic program of Atai Life Sciences (NASDAQ:ATAI) announced it has donated $500,000 to the Multidisciplinary Association for Psychedelic Studies (MAPS ...The atai Impact program will be initially funded by 1% of the gross proceeds from our June 2021 IPO and founders’ and shareholders’ contributions. Third Quarter 2021 Financial Results. Cash ...Oct 2, 2023 · NEW YORK and BERLIN, Oct. 06, 2023 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ: ATAI) (“atai”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, will participate in the Jefferies Inaugural Biotech CNS/Neuro Summit being held from October. October 6, 2023. Press Release. Clinical-stage biopharma company atai Life Sciences (NASDAQ: ATAI) reported the financial results for its first quarter ended March 31, 2023, and provided the period’s business highlights ...The fund has raised an initial $35 million in capital and currently holds an active portfolio of 20 companies, including investments in Atai Life Sciences (NASDAQ: ATAI), Reset Pharma, Field Trip ...Cathie Wood’s hedge fund dumped a whopping 5.6 million shares of Germany-based Atai Life Sciences N.V. (NASDAQ:ATAI) in the first quarter of 2023.Atai Life Sciences The Trade : Atai Life Sciences N.V. (NASDAQ:ATAI) Florian Brand acquired a total of 20,000 shares at an average price of $1.16. The insider spent around $23,120 to buy those shares.

Apr 13, 2023 · NEW YORK and BERLIN, April 13, 2023 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ: ATAI) (“atai”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental ... Other companies interested in the use of traditional, naturally derived ibogaine for substance abuse include DemeRx, a subsidiary of Peter Thiel-backed Atai Life Sciences (NASDAQ:ATAI), and ...Atai Life Sciences (NASDAQ:ATAI) has a somewhat unique business model, a decentralized platform that acquires and operates clinical programs that are separate companies or behave like them.Instagram:https://instagram. gooy dividendbest cash app stocks to invest in 2023stryker orthopaedics stockbanner life insurance reviews bbb October 6, 2023. NEW YORK and BERLIN, Oct. 06, 2023 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ: ATAI) (“atai”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, will participate in the Jefferies Inau... atai Life Sciences Announces Completion of Phase 1 Study of VLS-01 in Healthy ... cme fed fund futuresdow composite Nov 29, 2023 · According to 4 analysts, the average rating for ATAI stock is "Strong Buy." The 12-month stock price forecast is $13.5, which is an increase of 1,110.76% from the latest price. atai Life Sciences (NASDAQ: ATAI) (“atai”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, reported third quarter 2023 financial results and provided corporate updates. “As the burden of unmet medical needs in mental health care continues to grow, our team remains … what are rare quarters May 11, 2023 · The Company’s $250M cash position and committed term loan funding is expected to fund operations into 1H 2026. NEW YORK and BERLIN, May 11, 2023 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ ... Atai Life Sciences ( NASDAQ: ATAI) has a somewhat unique business model, a decentralized platform that acquires and operates clinical programs that are separate companies or behave like them. It ...Atai Life Sciences N.V. (NASDAQ:ATAI) is a promising clinical-stage biopharmaceutical company that creates and funds businesses focusing on developing psychedelic-based treatments.